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Abstract
Objectives
Therapy with mesenchymal stem cells exhibits potential for the development of novel
interventions for many diseases and injuries. The use of mesenchymal stem cells in
regenerative therapy for vocal fold scarring exhibited promising results to reduce stiffness
and enhance the biomechanical properties of injured vocal folds. This study evaluated the
biomechanical effects of mesenchymal stem cell therapy for the treatment of vocal fold
scarring.
Data Sources
PubMed, Embase, the Cochrane Library and Google Scholar were searched.
Methods
Controlled studies that assessed the biomechanical effects of mesenchymal stem cell ther-
apy for the treatment of vocal fold scarring were included. Primary outcomes were visco-
elastic properties and mucosal wave amplitude.
Results
Seven preclinical animal studies (n = 152 single vocal folds) were eligible for inclusion. Eval-
uation of viscoelastic parameters revealed a decreased dynamic viscosity (η’) and elastic
modulus (G’), i.e., decreased resistance and stiffness, in scarred vocal folds treated with
mesenchymal stem cells compared to non-treated scarred vocal folds. Mucosal wave
amplitude was increased in scarred vocal folds treated with mesenchymal stem cells vs.
non-treated scarred vocal folds.
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Conclusion
The results from these studies suggest an increased regenerative effect of therapy with
mesenchymal stem cells for scarred vocal folds and are encouraging for further clinical
studies.
Introduction
Parts of normal vocal fold (VF) tissue are often replaced with scar tissue during the healing
process after trauma, inflammatory disorders, iatrogenic lesions after surgery, and as a well-
known side-effect of the treatment of head and neck cancers with radiotherapy.[1]
The tissue in the wound healing process after any type of insult may be replaced by fibrous
scar tissue, which primarily consists of an excessive, disorganized extracellular matrix. The scar
tissue matrix is generally stiffer than the extracellular matrix it replaces. This matrix is of par-
ticular concern in areas surrounding and including the vocal folds because the normal func-
tions of these tissues depend on their elastic and vibratory properties.
True VFs are one of the most important structures used during normal phonation because
of their unique anatomic structure, which is essential for regulating the phonatory output.[2]
The mucosa is of particular interest because it is the most common site for injury.[3] Proteins
such as elastin, which is highly abundant in the elastic cone, and other extra cellular matrix
(ECM) proteins create a specialized pliable connective tissue that supports the viscoelasticity
of the VFs during vibration.[4] Diminished elasticity of the vocal folds reduces the ability to
phonate normally, which the patient will experience as a strained, weakened or hoarse voice.
The inability to phonate normally decreases both psychosocial and physical well-being.[3]
Increased mucosal stiffness is measured as a decreased dynamic viscosity and elastic modulus
using rheometry. Changes in the extracellular matrix, such as the change from highly organized
elastin to disorganized Type I collagen, primarily explain the change in phonation.[5] The
altered composition of ECM proteins is observed microscopically and correlates with macro-
scopically altered biomechanical properties, which also lead to changes in the mucosal waves
during phonation.[6–8] Notably, these altered biomechanical properties predict the quality of
phonation.[6]
However, the surgical and medical treatments to ameliorate the reduced functions of the
vocal folds after scarring produce limited effects. Therefore, the potential for regenerative ther-
apy using stem cells is of growing interest in the field.
Mesenchymal stem cells (MSCs), which were first described in the bone marrow to support
hematopoiesis,[9] are so-called adult stem cells that give rise to all cell types of mesodermal ori-
gin, such as osteocytes, chondrocytes and fibroblasts.[10] MSCs are isolated from a wide variety
of tissues, but these cells are most often harvested from adipose tissue (adipose-derived MSCs,
ASCs, AdMSCs) or bone marrow (bone marrow-derived MSCs, BM-MSCs).[11] MSCs have
received much attention over the past several decades, especially because of their immunomod-
ulatory, regenerative and trophic properties, but also because these cells are easily harvested
and expanded, the latter being a necessary function to obtain sufficient numbers of cells.[12,
13] The exact mechanism of action is not known, but various models of the therapeutic effects
of MSCs have been proposed. [12]
Several clinical trials with MSCs in various fields of regenerative medicine were performed,
and promising results with minimal side effects of the treatment were demonstrated.[12, 14–
16]
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Some studies used non-expanded cells from the fat-derived stromal vascular fraction (SVF),
which included a heterogeneous cell population of endothelial, hematopoietic and pericytic ori-
gin and only a minor fraction of adipose stem and precursor cells.[17]
Several types of therapies were evaluated to ameliorate the effects of scar tissue formation in
the VF, such as implantation of scaffolds and injection of growth factors.[18] No clinical trial
using MSCs for treating scar tissue formation on humans has been published. Several animal
studies have evaluated the effects of MSC therapy in reducing VF scarring. These studies
include evaluations of macroscopic scar formation and morphology, histological changes, tran-
scriptional upregulations, stem cell detection and functional outcomes. A comprehensive list of
all outcome measures from the preclinical studies may be found in S1 Table. The direct correla-
tion between the morphological, histological, and transcriptional changes and stem cell persis-
tence and the regenerative effect of the VFs cannot be performed, largely because of the
unknown mechanism of action of these stem cells. Therefore, we chose to evaluate the bio-
mechanical changes, which provide a more direct evaluation of VF function. This study sys-
tematically evaluated the literature on animal models concerning the biomechanical properties
and vibration patterns of scarred vocal folds after being injected with MSCs to evaluate their
potential in a future human trial.
Materials and Methods
Inclusion criteria
Controlled animal studies that evaluated MSCs as a treatment for vocal fold scarring and
included biomechanical measures were eligible for inclusion, regardless of the publication date.
Only publications in English were included. Unpublished clinical trials were accessed via Clini-
calTrials.gov. The outcome variables of interest were any type of viscoelastic or mucosal wave
measurement of the VFs after MSC treatment.
Search strategy
An electronic search was performed on PubMed, Embase, the Cochrane Library and Google
Scholar. The following keywords (MeSH terms included) were used: vocal folds or vocal cords
and stem cell or MSC or mesenchymal stem cell or processed lipoaspirate cell or stromal vascu-
lar fraction cell. The Search strategy appendix in S1 Appendix provides a detailed description
of the search strategy. The date of the last search was 1 April 2016.
The following data were extracted from the included studies: study design, randomization,
blinding, study participants, graft donor, source of graft, intervention, control groups, persis-
tence of the stem cell, statistical tests, biomechanical method, time after stem cell injection and
results from measurements of dynamic viscosity, elastic modulus and amplitude.
Results
The electronic searches identified 118 potentially eligible studies, only seven of which [19–25]
met the inclusion criteria (Fig 1). These seven studies, which addressed 152 single VFs in 76
animals, were included in the qualitative analysis. Tables 1 and 2 summarizes the interventions
and study designs. All studies were controlled animal studies. One study reported a blinded
evaluation of the results, and three studies reported randomization of animals into the inter-
vention or control group. Six of the studies examined rabbit vocal folds, and one study investi-
gated vocal folds in dogs. Bone-marrow derived MSCs were used in six studies, and one study
used adipose-derived MSCs. Three studies examined a combined approach with MSCs and
small intestinal submucosa, hyaluronic acid/cross-linked alginate hydrogel or an atelocollagen
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sponge. The stem cells were injected directly into the injured area of the vocal fold in six stud-
ies, and the cells were implanted in combination with an atelocollagen sponge at the injured
site in one study. Only one study used autologous MSCs, and five studies used xenotrans-
planted MCSs from another animal or human MSCs. One study used allogeneic MSCs. The
immunosuppressive drug tacrolimus was injected into the animals in three studies to minimize
the risk of rejection of the injected stem cells.
The species, source of the stem cell graft, evaluation time, disease model, intervention and
statistical tests varied significantly across the studies, and a meta-analysis would be meaningless.
Biomechanical outcomes after treatment of VF scarring with MSCs
Five of the studies reported biomechanical measures, e.g., dynamic viscosity and elastic modu-
lus, after the induction of VF scarring. Table 3 describes these results. Two study groups per-
formed these five studies: [20, 24, 25] and [21, 22]. Notably, the cell dose in reference [22]
differed 10-fold from the other studies.
Two of these five studies reported a statistically significant improvement in dynamic viscos-
ity in the MSC-treated group versus a saline-treated control group. The difference in dynamic
viscosity was only marginally significant in one study (P = 0.07), but it was insignificant in the
other study (P = 0.2). The last study did not report a comparison between the MSC-treated and
saline control groups.
Five studies compared elastic modulus measurements in an MSC-treated group versus a
saline-treated control group. Three of these studies demonstrated a significant improvement in
elastic modulus in the MSC-treated group versus the saline control group, but one study did
Fig 1. PRISMA chart.
doi:10.1371/journal.pone.0162349.g001
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Table 1. Overview of studies.
Author
(year)
[reference]
Study design Animal (VFs in control
and intervention)
Graft donor
source
Origin of
MSCs
Intervention(s) Disease model of
scarring
Control group
(s)
Choi et al
(2014) [19]
Controlled trial Rabbits (24 rabbits were
included, with bilateral
scarring of VFs. The
control was the left VF,
leaving 8 VFs per
intervention)
Rabbit MSCs
and SIS from
pig
Bone
marrow
1. Injection of 2x107
MSCs mixed with
SIS powder
2. Injection with
2x107 MSCs
3. Injection with SIS
powder
Scarring of vocal folds
with electrocoagulator
1. A group with
scarring
without
interventions
Hertegård
et al (2006)
[20]
Controlled trial Rabbits (10 rabbits were
included of which 12 VFs
were scarred and 8 were
left unscarred)
Human Bone
marrow
1. Injection with
8x104 MSCs.
The MSC treated
animals were
also given
tacrolimus
2. Injection with
saline
Scarring of vocal folds
with localized excision of
the mucosa and
superﬁcial thyroarytenoid
muscle with micro
scissors
1. A group with
saline
injection of
scarred vocal
folds
2. A group
without
scarring that
were left
untreated
Kim et al
(2013) [21]
Randomized,
controlled trial
Rabbits (24 rabbits were
included, 8 were
uninjured, 4 were
unilaterally scared and 4
were bilaterally scarred
leaving 8 animals
unaccounted for)
Mice Bone
marrow
1. Injection of 1x105
MSCs
2. Injection of PBS
Excision of the VF
epithelium and lamina
propria with micro cup
forceps
1. A group
without
scarring of
VFs
2. A group with
scarred vocal
folds treated
with PBS
Kim et al
(2014) [22]
Randomized,
controlled,
blinded trial
Rabbits (40 animals in
total, 8 per group,
leaving 16 VFs per
group)
Human Adipose
tissue
1. Injection of 1x106
MSCs
2. Injection with
1x106 MSCs and
HA/ALG
3. Injection with
PBS
4. Injection with HA/
ALG
Excision of the VF
epithelium and lamina
propria using
microsurgical instruments
1. A group
without
scarring
2. A group with
scarred VFs
treated with
PBS
Ohno et al
(2011) [23]
Randomized,
controlled trial
Dogs (12 dogs, with 8
receiving bilateral
scarring of VFs, and 4
with unilateral scarring)
Dog MSCs and
human
atelocollagen
Bone
marrow
1. Implantation of
1x106 MSCs in
an atelocollagen
sponge
2. Implantation of
atelocollagen
sponge
Stripping of the epithelium
and lamina propria to the
thyroarytenoid muscle
with micro scissors and
micro forceps
1. A group with
no scarring
Svensson
et al (2010)
[24]
Controlled trial Rabbits (11 rabbits,
where eighteen VFs
were scarred and 4 were
left unscarred)
Human Bone
marrow
1. Injection of 0.8-
1x105 MSCs and
afterwards
tacrolimus
2. Injection of saline
Excision of the mucosa
and superﬁcial layer of the
thyroarytenoid muscle
with micro cup forceps
1. A group with
saline
injection in
scarred vocal
folds
2. A group
without
scarring
(Continued)
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not demonstrate an improvement (P = 0.34). The last study did not report the statistics of this
comparison.
None of the studies reported a measure of the magnitude of the difference, such as a fold-
change or percentage difference, in dynamic viscosity or elastic modulus in the MSC-treated
versus saline control group. Two of the studies that compared the viscoelastic results in an
MSC-treated group versus a normal control group that was not VF scarred demonstrated that
Table 1. (Continued)
Author
(year)
[reference]
Study design Animal (VFs in control
and intervention)
Graft donor
source
Origin of
MSCs
Intervention(s) Disease model of
scarring
Control group
(s)
Svensson
et al (2011)
[25]
Controlled trial Rabbits (12 rabbits in
total, of which 20 VFs
were scarred and 4 VFs
were unscarred controls
Human Bone-
marrow
1. Injection of 0.8-
1x105 MSCs and
afterwards
tacrolimus.
2. Saline
Excision of the mucosa
and superﬁcial layer of the
thyroarytenoid muscle
with micro cup forceps
1. An unscarred
group
2. A scarred
group treated
with saline
VFs, vocal, MSC, Mesenchymal stem cell, SIS, small intestine submucosa, PBS, phosphate-buffered saline, HA, Hyaluronic acid, ALG, mildly cross-linked
alginate hydrogel
doi:10.1371/journal.pone.0162349.t001
Table 2. Overview of studies (continued).
Author (year)
[reference]
Intervention(s) Persistence of cells Statistical tests
Choi et al (2014)
[19]
1. Injection of 2x107 MSCs mixed with SIS
powder
2. Injection with 2x107 MSCs
3. Injection with SIS powder
1. > 8 weeks
2. > 8 weeks
• One way analysis of variance (ANOVA): analysis
between comparative groups
• Tukey-HSD test: difference between mean values
• Coefﬁcient of correlation test: analysis of mean value
• Student T-test: analysis of mean value
Hertegård et al
(2006) [20]
1. Injection with 8x104 MSCs. The MSC treated
animals were also given tacrolimus
2. Injection with saline
1. At 4 weeks; 0,18
engraftment
• Nonparametric comparisons between the groups
• Wilcoxon: comparison of mean values
Kim et al (2013)
[21]
1. Injection of 1x105 MSCs
2. njection of PBS
1. > 4 weeks • Mann-Whitney test: differences between two groups
• Kruskal-Wallis test + post hoc - - Dunn’s test:
comparison of the values among the tree groups
Kim et al (2014)
[22]
1. Injection of 1x106 MSCs
2. Injection with 1x106 MSCs and HA/ALG
3. Injection with PBSInjection with HA/ALG
1. > 1 month
2. > 1 month
• The Mann-Whitney test: signiﬁcance of differences
between two groups
• Kruskal-Wallis test + Dunns’ post hoc test: comparison
of the three groups
• Bonferroni’s post hoc test: analysis of rheological data
using two-way analysis of variance
Ohno et al (2011)
[23]
1. Implantation of 1x106 MSCs in an
atelocollagen sponge
2. Implantation of atelocollagen sponge
1. Not measured • Paired r-test: differences in the NMWA
• Welch's i-test: differences in CR-NMWA
Svensson et al
(2010) [24]
1. Injection of 0.8-1x105 MSCs and afterwards
tacrolimus
2. Injection of saline
1. At 3 months: no
detectable MSCs
• Mann-Whitney U test: nonparametric comparisons
Svensson et al
(2011) [25]
1. Injection of 0.8-1x105 MSCs and afterwards
tacrolimus
2. Saline
1. At 10 weeks: no
detectable MSCs
• Mann–Whitney U test: differences between two
groups
• Binomial test: differences between the three groups
• F test: regressions analysis
doi:10.1371/journal.pone.0162349.t002
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neither the elastic modulus nor the dynamic viscosity between the scarred VFs treated with
MSCs and a group of animals with normal unscarred VFs was significantly different. These
results suggest that most or all of the negative impact of scarring on the biomechanical proper-
ties of the VFs was ameliorated. However, this outcome was not always reported or measured.
Mucosal wave amplitude after treatment of VF scarring with MSCs
Three studies reported measurements of the mucosal wave amplitude after induction of VF
scarring. Table 4 describes these results. However, none of these studies reported statistics of
the comparison between MSC-treated versus saline in scarred VFs. These studies only reported
findings from the comparison between a combined approach of either MSC+SIS versus SIS/
MSC or MSC + atelocollagen versus sham, which resulted in a statistically significant improve-
ment versus a control group. None of the studies reported a measure of the magnitude of the
difference between the MSC-treated versus saline-treated VFs. Therefore, it is difficult to evalu-
ate whether the observed differences between the control group and the MSC-treated group
were clinically relevant. However, a few of the studies reported a comparison between the
MSC-treated group versus a group with unscarred VFs, and these studies did not find a signifi-
cant difference between the MSC-treated group and the non-scarred group, which indicates
that the intervention resulted in a relevant amelioration of mucosal wave function after inter-
vention with MSCs.
Use of MSCs for the treatment of acute or chronic vocal fold scarring
MSCs were injected into animal VFs on the same day as the scarring was performed in six of
the seven studies. Therefore, these studies include the possibility of reducing scar tissue forma-
tion from the onset of healing, when a known insult to vocal fold tissue is performed. Only one
study investigated the possibility of reducing already manifested scar tissue. The VFs in this
model were scarred and left to heal with scarring for 9 weeks before surgically removing the
scar tissue and injecting MSCs into the VFs during the same procedure. It is difficult to know
in advance whether a given insult to human VFs will result in significant scar tissue formation.
Therefore, this last model represents a more relevant model for the treatment of VF scarring
using MSCs.
Disease models used to induce scar tissue formation
Six of the studies used surgical instruments to induce scarring. However, the procedure was
not described in detail regarding the extent of the insult, but most of the studies suggest that
the entirety of the mucosa and lamina propria was removed. Some or most of the thyroaryte-
noid muscle was also surgically removed in four studies. Scar tissue formation was induced
using an electrocoagulator in one study. The healing process during inflammatory disorders
Table 4. Study results frommucosal wavemeasurement.
Testing method Author (year)
[reference]
Time from wounding to
intervention
Time from intervention to
biomechanical testing
Comparisons P-value
Mucosal wave measurement,
videokymography
Choi et al (2014)
[19]
0 days 8 weeks 1. MSC vs. MSC
+ SIS
2. MSC vs. control
1. P < 0.01
2. Not
reported
Mucosal wave measurement,
videokymography
Kim et al (2014)
[22]
0 days 1 and 3 months MSC vs. PBS Not
reported
Mucosal wave measurement, high-
speed digital-imaging
Ohno et al (2011)
[23]
0 days 6 months MSC + atelocollagen
vs. sham
P < 0.01
doi:10.1371/journal.pone.0162349.t004
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or after radiotherapy is different than surgically induced scars, but whether the treatment of
scarred VFs after these types of insult would result in the same outcomes as these studies can-
not be assessed.
The persistence of the injected MSCs
The injected cells were detected at the evaluation time in four of the seven studies. Two of the
seven studies detected no MSCs at the evaluation time, and no measurement of the persistence
was performed in one study. Whether the presence or absence of the MSCs correlated to the
effect of the injected stem cells is not known because of the largely unknown mechanism of
action.
Clinical trials evaluating the use of MSCs for the treatment of vocal fold
scarring
The electronic search identified two on-going clinical trials, [26, 27] but none of the studies
reported any preliminary data (Table 5). The first study is a phase I study used autologously
expanded BM-MSC injections into patients with dysphonia and scarred vocal folds. The other
study used adipose-derived SVFs that were directly injected into scarred vocal folds. Both stud-
ies evaluated biomechanical parameters of the vocal folds and voice quality.
Discussion
To the best of our knowledge, this study is the first systematic review of functional outcomes
after mesenchymal stem cell treatment of VF scarring. No clinical trials have evaluated the
effect of stem cell injections, and therefore, our results are based on preclinical animal studies.
The use of MSCs in the treatment of vocal fold scarring is a complex research field, and several
factors must be considered when evaluating the effect of MSC in the treatment of VF dysfunc-
tion after scarring. These factors include the type and dose of MSCs (adipose-derived or bone-
marrow derived), the origin of MSCs (xenogeneic, allogeneic or autologous), the study design
(acute or chronic scarring), and the disease model (surgery or electro coagulation to induce
scarring). Three of the studies primarily examined a combined approach with MSCs and a type
of scaffold or ECM protein, but these studies did not report the statistics of the comparison
between an MSC-treated group versus saline-treated group although these experiments were
performed. These methodological differences make it difficult to summarize the findings into a
coherent conclusion. Potential biases in the studies were also a concern because only a few
of the studies reported the randomization of animals into treated or control groups, and
none specified how the randomization was performed. Only one study reported blinding.
Table 5. Overview of clinical trials.
Reference Study type
(n = estimated
enrolment)
Intervention Phase Status Outcomemeasures
Karolinska
UH. [26]
Clinical, single-group,
open labelled (n = 25)
Injection of autologous BM-MSC
(aMSC) or aMSC with a
hyaluronan gel in patients with
vocal fold scarring
I Recruiting Safety, efﬁcacy. Healing detection: inﬂammation,
polyp/granuloma formation, blood sample
evaluation. Functional measures: high-speed
imaging, acoustic voice analysis, phonation
pressure measurement.
Assistance
PHDM. [27]
Clinical, single-group,
open labelled (n = 8)
Injection of autologous stromal
vascular fraction (SVF) in patients
with vocal fold scarring
Not
speciﬁed
Not yet
recruiting
Feasibility, safety, efﬁcacy. Functional measures:
Voice handicap index evaluation,
laryngostroboscopy
doi:10.1371/journal.pone.0162349.t005
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Five of the seven studies evaluated the biomechanical properties of excised VFs, and most of
these studies reported improvement in the MSC-treated group. However, not all of the studies
reached statistical significance. Whether this difference in statistical significance was related to
the low power used to detect a difference or methodological differences cannot be evaluated.
Three of the studies examined mucosal wave patterns after an intervention with MSCs, and
most of these studies reported an apparent improvement. However, only one study reported
the statistics (P< 0.01) for the comparison between the MSC- and saline-treated control
groups. The significance of the comparisons in the two remaining studies was not reported.
Taken together, the above-mentioned findings are encouraging for further studies. There are
some fundamental limitations in the animal studies that will make it difficult to evaluate whether
human trials with MSCs will lead to clinically relevant improvements in phonation following an
MSC treatment. First, six of the seven studies evaluated the reduction of scar tissue formation in
the acute phase of healing. It is unlikely that this timeframe represents a relevant model of the
treatment of human VF scarring. A relevant model would require the administration of MSCs
during a planned insult to the VFs, which may be relevant in some, but not all clinical scenarios.
It is unlikely that MSC treatment would be given before an observation period to assess any
spontaneous improvement in phonation before offering any treatment because of the relative
complexity of the current autologous MSC treatments. Only one study investigating the effect of
MSC treatment of chronic scar tissue formation has been published, and this study reported
encouraging improvements in biomechanical properties following MSC treatment. Studies com-
paring time perspectives of the injection of stem cells in relation to the specific trauma should be
performed to obtain a treatment regimen focused on the exact cause of the VF lesion.
We identified one other review of vocal fold regeneration. This review primarily focused on
histological changes following MSC treatment with various types of scaffolds and growth fac-
tors.[3] The correlation between histological changes and phonation is not straightforward.
Therefore, we only focused on functional outcome measures, which exhibits a proven correla-
tion with phonation, such as measures of a dysfunction, e.g., hoarseness and an easily fatigued
voice. The mechanism of action is largely unknown, and further research on the exact effect of
stem cell injection could clarify the results from the animal studies, such as histological changes
and the persistence of the stem cells.
The results of the two uncompleted clinical trials, one using expanded MSCs and the other
using the heterogeneic SVF cell population, should provide useful results in the field, especially
for assessments of safety concerns and feasibility. However, the limited number of clinical stud-
ies indicates that much more research is necessary to provide evidence of MSC therapy for the
treatment of scarred vocal folds. The authors are currently designing a prospective, blinded
clinical trial of the injection of mesenchymal-derived stem cells perioperatively in Reinke’s
edema patients.
In conclusion, animal studies of MSC treatment of scarred vocal folds reveal encouraging
results for biomechanical and mucosal wave measurements. These results should be viewed
cautiously with the limitations in the included studies, such as statistical insignificance, great
intervention variance and the existence of potential biases. Whether these results will translate
to improved phonation in human trials with MSC treatment for vocal fold scarring is currently
not known. The results from the two on-going clinical trials with MSCs for VF dysfunction
should answer some of these questions and are awaited with great interest.
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